Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Wieslander, E; Knoos, T
   A virtual linear accelerator for verification of treatment planning systems
   PHYSICS IN MEDICINE AND BIOLOGY
   
   E. Wieslander e T. Knoos, "A virtual linear accelerator for verification of treatment planning systems", PHYS MED BI, 45(10), 2000, pp. 2887-2896
2. WIESLANDER E; DELANDER EL; JARKELID L; HJERTBERG E; TUNEK A; BRATTSAND R
   PHARMACOLOGICAL IMPORTANCE OF THE REVERSIBLE FATTY-ACID CONJUGATION OF BUDESONIDE STUDIED IN A RAT-CELL LINE IN-VITRO
   American journal of respiratory cell and molecular biology
   
   E. Wieslander et al., "PHARMACOLOGICAL IMPORTANCE OF THE REVERSIBLE FATTY-ACID CONJUGATION OF BUDESONIDE STUDIED IN A RAT-CELL LINE IN-VITRO", American journal of respiratory cell and molecular biology, 19(3), 1998, pp. 477-484
3. WIESLANDER E; ENGMAN L; SVENSJO E; ERLANSSON M; JOHANSSON U; LINDEN M; ANDERSSON CM; BRATTSAND R
   ANTIOXIDATIVE PROPERTIES OF ORGANOTELLURIUM COMPOUNDS IN CELL SYSTEMS
   Biochemical pharmacology
   
   E. Wieslander et al., "ANTIOXIDATIVE PROPERTIES OF ORGANOTELLURIUM COMPOUNDS IN CELL SYSTEMS", Biochemical pharmacology, 55(5), 1998, pp. 573-584
4. MCKAY DM; BRATTSAND R; WIESLANDER E; FUNG M; CROITORU K; PERDUE MH
   BUDESONIDE INHIBITS T-CELL-INITIATED EPITHELIAL PATHOPHYSIOLOGY IN ANIN-VITRO MODEL OF INFLAMMATION
   The Journal of pharmacology and experimental therapeutics
   
   D.M. Mckay et al., "BUDESONIDE INHIBITS T-CELL-INITIATED EPITHELIAL PATHOPHYSIOLOGY IN ANIN-VITRO MODEL OF INFLAMMATION", The Journal of pharmacology and experimental therapeutics, 277(1), 1996, pp. 403-410
5. MCKAY DM; BRATTSAND R; WIESLANDER E; PERDUE MH
   BUDESONIDE INHIBITS IMMUNE CELL ACTIVATION AND EPITHELIAL PATHOPHYSIOLOGY IN COCULTURE STUDIES
   Gastroenterology
   
   D.M. Mckay et al., "BUDESONIDE INHIBITS IMMUNE CELL ACTIVATION AND EPITHELIAL PATHOPHYSIOLOGY IN COCULTURE STUDIES", Gastroenterology, 108(4), 1995, pp. 873-873
6. MAIN C; BRATTSAND R; JARKELID L; WIESLANDER E
   NEUTROPHIL-MEDIATED IMPAIRMENT OF COLONIC EPITHELIAL-CELL (CACO-2) BARRIER FUNCTION - EFFECTS OF PROTEASE INHIBITORS AND ANTIOXIDANTS
   Gastroenterology
   
   C. Main et al., "NEUTROPHIL-MEDIATED IMPAIRMENT OF COLONIC EPITHELIAL-CELL (CACO-2) BARRIER FUNCTION - EFFECTS OF PROTEASE INHIBITORS AND ANTIOXIDANTS", Gastroenterology, 106(4), 1994, pp. 10000727-10000727
7. WIESLANDER E; MAIN C; JARKELID L; BRATTSAND R
   EFFECTS OF ACTIVATED PHAGOCYTES ON A CULTURED COLONIC EPITHELIAL-CELLLINE, CACO-2
   Gastroenterology
   
   E. Wieslander et al., "EFFECTS OF ACTIVATED PHAGOCYTES ON A CULTURED COLONIC EPITHELIAL-CELLLINE, CACO-2", Gastroenterology, 104(4), 1993, pp. 801-801